In terms of the sustainability of therapeutic effects, the genetically introduced channel rhodopsin could not stop RP, so that the benefit is lost with progressing retinal degeneration1 while vision provided from subretinal implants43 with a technically overhauled implant Alpha AMS, remains stable over a long period. This evidence concerns the gene RHO and retinitis pigmentosa 1.